High GHET1 expression was also associated with low sensitivity to the chemotherapy drug gemcitabine in BLCA patients, and it was highly expressed in gemcitabine-resistant BLCA cell lines. This evidence concerns the gene GHET1 and bladder transitional cell carcinoma.